Evidence map›Paper›PMID 38449698›Full record

ArticleNarra J2022

Acceptance and willingness to purchase a hypothetical COVID-19 vaccine in a region under Shariah law: A cross-sectional study in Aceh, Indonesia.

Muhammad A Rayhan, Mudatsir Mudatsir, Nurjannah Nurjannah, Ichsan Ichsan, Mehrdad Amir-Behghadami, Yousef S Khader, Ai Koyanagi, Ranjit Sah, Sandro G Viveiros-Rosa, Mohammed A Mamun and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Narra J, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 16 countries.

Muhammad A RayhanSchool of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.
Mudatsir MudatsirDepartment of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.
Nurjannah NurjannahDepartment of Public Health, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.
Ichsan IchsanDepartment of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.
Mehrdad Amir-BehghadamiIranian Center of Excellence in Health Management, Department of Health Service Management, School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran.
Yousef S KhaderJordan University of Science and Technology, Irbid, Jordan.
Ai KoyanagiResearch and Development Unit, Parc Sanitari Sant Joan de Déu, ICREA, CIBERSAM, ISCIII, Barcelona, Spain.
Ranjit SahTribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu Nepal.
Sandro G Viveiros-RosaPharmacy Division, Instituto Nacional da Propriedade Industrial, Rio de Janeiro, Rio de Janeiro, Brazil.
Mohammed A MamunDepartment of Public Health and Informatics, Jahangirnagar University, Dhaka, Bangladesh.
Yohannes K LemuDepartment of Health, Behavior and Society, Faculty of Public Health, Jimma University, Ethiopia.
Assarag BouchraNational School of Public Health, Rabat, Morocco.
Laure Sg LinguissiInstitut National de Recherche en Science de la Santé, Brazzaville, Republique of Congo.
Aamer IkramNational Institutes of Health, Islamabad, Pakistan.
Dina E SallamPediatrics and Pediatric Nephrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Konstantinos ParperisDepartment of Internal Medicine, University of Cyprus Medical School, Nicosia, Cyprus.
Uwe WollinaDepartment of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital, Dresden, Germany.
Marius RademakerClinical Trials New Zealand, Hamilton, New Zealand.
Sandro VentoFaculty of Medicine, University of Puthisastra, Phnom Penh, Cambodia.
Said UsmanDepartment of Public Health, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.
Universitas Syiah Kuala · IDAin Shams University · EGCentro de Investigación Biomédica en Red de Salud Mental · ESClinical Trials New Zealand · NZInstituto Nacional da Propriedade Industrial · BRJahangirnagar University · BDJimma University · ETJordan University of Science and Technology · JOLaboratoire National de Santé Publique du Congo · CGNational Institute of Health · PKNational School of Architecture · MAStädtisches Klinikum Dresden · DETabriz University of Medical Sciences · IRTribhuvan University Teaching Hospital · NPUniversity of Cyprus · CYUniversity of Puthisastra · KH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccines are urgently needed to control the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to determine the acceptance of and willingness to purchase a hypothetical COVID-19 vaccine in the general population of Aceh, a holistic Shariah law implementation province in Indonesia. An online cross-sectional study was conducted using a quota sampling technique between 1 to 24 September 2021. To determine hypothetical vaccine acceptance, respondents were asked if they were willing to accept vaccines with combinations of either 50% or 95% effectiveness and either 5% or 20% risk of adverse effects. Willingness to purchase was assessed by asking whether the participants would pay for such vaccines at certain price points. Logistic regression analysis was used to assess the associated determinants. Out of 377 respondents included in the final analysis, 86.5% were willing to accept a COVID-19 vaccine with 95% effectiveness and 5% adverse effects. The acceptance rate dropped to 45.1% if the risk of adverse effects was 20%. Vaccines with 50% effectiveness and 5% adverse effects were acceptable to 42.2% but the acceptance went down to 17.2% if the risk of adverse effects increased to 20%. Multivariate analysis found that men were twice as likely to accept a vaccine with 95% effectiveness and 5% adverse effects compared to females (aOR: 2.01; 95% CI 1.05-3.86). We found that 156/377 (41.3%) of respondents were willing to purchase a COVID-19 vaccine and of these participants 71.1% were willing to pay between Indonesian Rupiah (IDR) 50,000-150,000 (US$ 3.33-10.00). In conclusion, the acceptance rate of a hypothetical COVID-19 vaccine varied based on effectiveness and the risk of adverse effects.

Indexed as

AcceptanceCOVID-19Syariah lawvaccinewillingness to purchase

Identifiers

PMID38449698
PMCPMC10914119
OpenAlexW4289526069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.